EU-FDA MRA: Soon all States on board
Recommendation
14/15 October 2026
Vienna, Austria
Quality Oversight of Pharmaceutical Contract Manufacturing Organisations
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The Mutual Recognition Agreement (MRA) with the USA was supplemented by two further countries: Poland and Slovenia. Now 22 countries are already recognised. Among other countries, Germany is still missing . On a dedicated webpage of the EMA there is an excellent overview. By 15 July 2019, however, all authorities and countries should have been inspected and approved.
If the agreement is fully in force (and only then!), the additional full testing of a drug imported from the USA will no longer be necessary. This also applies to countries that have already been recognised.
No more inspections?
In exceptional cases, the FDA will continue to travel to the EU for inspections, among other things within the framework of approval procedures (so-called pre-approval inspections). This also became clear at an ECA conference in November 2018, where participants from Spain, Austria and Denmark reported on announced inspections for the year 2019.
Related GMP News
23.09.2026FDA Inspection as GMP Evidence? Swissmedic Opens Up a New Option
23.09.2026New: Coordination of GMP Inspections for Centrally Authorised Products
16.09.2026How GMP Non-Compliance can stop a Marketing Authorisation Application
10.09.2026FDA Warning Letter: Inadequate Warehouse Controls and Lot Traceability
09.09.2026Specified Microorganisms and More - FDA Warning Letter